Osiris Therapeutics, Inc. (OSIR) Financial Statements (2024 and earlier)

Company Profile

Business Address 7015 ALBERT EINSTEIN DRIVE
COLUMBIA, MD 21046
State of Incorp. MD
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2018
12/31/2017
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments27,88850,10459,01034,092
Cash and cash equivalents3,0812,2082,4161,854
Short-term investments24,80747,89656,59432,238
Receivables30,84134,2587,4593,063
Inventory, net of allowances, customer advances and progress billings11,27810,9241,9291,278
Inventory11,27810,9241,9291,278
Disposal group, including discontinued operation   91 
Prepaid expense and other current assets603
Other undisclosed current assets2,92065015,620 
Total current assets:72,92795,93684,10939,036
Noncurrent Assets
Property, plant and equipment3,5872,0871,8962,111
Restricted cash and investments   243317
Other noncurrent assets   
Deferred tax assets, net    
Other undisclosed noncurrent assets 1,608955,849 
Total noncurrent assets:5,1952,1827,9882,428
TOTAL ASSETS:78,12298,11892,09741,464
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:14,6688,8544,8424,999
Accounts payable5,269   
Accrued liabilities9,399   
Other undisclosed accounts payable and accrued liabilities  8,8544,8424,999
Debt  454544
Deferred compensation liability  1,667  
Disposal group, including discontinued operation   57 
Deferred tax liabilities   5,849 
Other liabilities1,934   
Other undisclosed current liabilities18,500   
Total current liabilities:35,10210,56610,7935,043
Noncurrent Liabilities
Long-term debt and lease obligation  72117162
Capital lease obligations  72117162
Liabilities, other than long-term debt1,6263,589355369
Other liabilities1,6263,589355369
Other undisclosed noncurrent liabilities  (72)(117) 
Total noncurrent liabilities:1,6263,589355531
Total liabilities:36,72814,15511,1485,574
Equity
Equity, attributable to parent41,39483,96380,94935,890
Common stock35353433
Additional paid in capital283,905287,525282,702279,269
Accumulated other comprehensive loss(208)(54)(33)(20)
Accumulated deficit(242,338)(203,543)(201,754)(243,392)
Total equity:41,39483,96380,94935,890
TOTAL LIABILITIES AND EQUITY:78,12298,11892,09741,464

Income Statement (P&L) ($ in thousands)

12/31/2018
12/31/2017
12/31/2014
12/31/2013
12/31/2012
Revenues118,51459,86724,94711,804
Revenue, net118,51459,86724,94711,804
Cost of revenue
(Cost of Goods and Services Sold)
(32,681)(13,452)(6,718)(2,576)
Gross profit:85,83346,41518,2299,228
Operating expenses(87,822)(44,978)(20,485)(20,404)
Other undisclosed operating income (loss)  281(577)25
Operating income (loss):(1,989)1,718(2,833)(11,151)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(645)(1,771)41449
Income (loss) from continuing operations before income taxes:(2,634)(53)(2,419)(11,102)
Income tax expense (benefit)1,398(193)1,32637
Income (loss) from continuing operations:(1,236)(246)(1,093)(11,065)
Income (loss) before gain (loss) on sale of properties:(1,236)(1,187)(1,093)(11,065)
Income (loss) from discontinued operations (941)  
Other undisclosed net income 10,021   
Net income (loss) attributable to parent:8,785(1,187)(1,093)(11,065)
Other undisclosed net income (loss) available to common stockholders, basic  (602)42,731 
Net income (loss) available to common stockholders, diluted:8,785(1,789)41,638(11,065)

Comprehensive Income ($ in thousands)

12/31/2018
12/31/2017
12/31/2014
12/31/2013
12/31/2012
Net income (loss):8,785(1,187)(1,093)(11,065)
Comprehensive income (loss):8,785(1,187)(1,093)(11,065)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(119)(623)42,718(40)
Comprehensive income (loss), net of tax, attributable to parent:8,666(1,810)41,625(11,105)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: